Higher Rates Of Amputation And Ketoacidosis With Sglt2 Inhibitors: European Registry Data | Latest News RSS feed

Higher Rates Of Amputation And Ketoacidosis With Sglt2 Inhibitors: European Registry Data - Latest News


Higher risk for amputation, DKA with SGLT2 inhibitors for T2DM

Data ... SGLT2 inhibitors correlated with an increased risk for lower-limb amputation (incidence rate ratio, 2.7 versus 1.1 events per 1,000 person-years; hazard ratio [HR], 2.32; 95 percent confidenc... read more

J&J says real-world data finds no amputation risk for Invokana

A year ago, regulators slapped warnings to the labelling for Johnson & Johnson’s diabetes drug Invokana, setting it at a disadvantage against rival drugs in the SGLT2 inhibitor ... lower-limb amputati... read more

Zackary Berger’s weekly research reviews—19 November

Perhaps because only chain pharmacies were contacted, or because telephone rather than in-person data were collected, the availability was higher ... SGLT2 inhibitors were lower limb amputations and d... read more

Looking for another news?


Bolstering your armamentarium with SGLT2 inhibitors

25 In a pooled analysis of 12 dapagliflozin trials, the rates of GMIs in all patients were higher with dapagliflozin than with placebo (5.1% versus 0.9%). 23 Pooled data from 17 ... susceptibility to ... read more


Portugal's RRT Incidence Rate Is Highest in Europe

Portugal has the highest incidence rate of renal replacement therapy ... had the lowest (146.7 pmp). The ERA-EDTA Registry collected data from national and regional registries in 30 countries in Europ... read more

Certain diabetes drugs linked to increased risk of lower limb amputation

Use of sodium glucose cotransporter 2 (SGLT2) inhibitors to treat type 2 diabetes is associated with an increased risk of lower limb amputation and diabetic ketoacidosis (a serious ... team analysed n... read more

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

The number of adjudicated diabetic ketoacidosis events was comparable between empagliflozin 2.5 mg and placebo and higher than placebo in adults ... Empagliflozin is an SGLT2 inhibitor used along with ... read more

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

The CANVAS Program integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular ... of canagliflozin and other SGLT2 inhibitors. 5 The increase... read more

Novo Nordisk A/S (NVO) Q1 2018 Results - Earnings Call Transcript

Where what happens is that as the SGLT-2 inhibitor takes down glucose levels ... labels and say there are elements of slight risk of diabetic ketoacidosis, some overrepresentation of amputations, some ... read more

Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes

In the post hoc analysis of 18-week data ... of SGLT2 inhibitors as early therapy in patients with type 2 diabetes. Results from large-scale cardiovascular safety studies of incretin-based therapies a... read more

Metformin Benefits Diabetics with Heart Failure

The findings are based on data from a large general practice registry often used in studies examining the ... The GPRD is known for hits high-quality information on co-morbidities and therapy. The ana... read more

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes

The rate of diabetic ketoacidosis was higher in the sotagliflozin group than in the placebo group (3.0% [21 patients] and 0.6% [4], respectively). Sotagliflozin (LX4211) is a new oral inhibitor of sod... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us